Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Celltrion Cuts Deal With Jordan-based Hikma To Sell Its Biosimilars In The Middle East, Africa

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Days after finalizing a deal to sell biosimilar therapeutic antibodies in Israel, Korea's Celltrion has signed a similar agreement with Jordan-based Hikma Pharmaceuticals to market the products across 17 Middle East and Northwestern African countries
Advertisement

Related Content

Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East
Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East
Korea's Celltrion Banks On Increasing Profits Resulting From New Focus On Biosimilars
Korea's Celltrion Banks On Increasing Profits Resulting From New Focus On Biosimilars
Korea FDA Approves Roche's Herceptin For First-line Metastatic Gastric Cancer
Korea FDA Approves Roche's Herceptin For First-line Metastatic Gastric Cancer
Korea's Celltrion Cuts Deal With Perrigo To Sell Its Biosimilars In Israel
Korea's Celltrion Gains Foothold in Europe; Wins Clinical Trial Approval from Latvia For Herceptin Biosimilar
Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions
Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions
Advertisement
UsernamePublicRestriction

Register

SC074532

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel